Stock Analysis, Dividends, Split History

VRA / Vera Bradley, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price15.95
Volume330,600.00
Market Cap ($M)562.27
Enterprise Value ($M)481.19
Book Value ($M)292.15
Book Value / Share8.26
Price / Book1.92
NCAV ($M)192.50
NCAV / Share5.44
Price / NCAV2.64
Share Statistics
Common Shares Outstanding 35,519,809
Common Stock Shares Outstanding 35,459,000
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.02
Balance Sheet (mrq) ($M)
Assets359.35
Liabilities67.20
Quick Ratio4.09
Current Ratio6.12
Income Statement (mra) ($M)
Revenues454,648,000.00
Operating Income14.98
Net Income7.02
Earnings Per Share Diluted0.19
Earnings Per Share Basic0.20
Cash Flow Statement (mra) ($M)
Cash From Operations42.64
Cash from Investing-51.60
Cash from Financing-51.60
Identifiers and Descriptors
CUSIP92335C106
Central Index Key (CIK)1495320
Related CUSIPS
92335C956 92335C906

Split History

Stock splits are used by Vera Bradley, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Is Vera Bradley (VRA) Outperforming Other Retail-Wholesale Stocks This Year?

2018-09-20 zacks
The Retail-Wholesale group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Vera Bradley (VRA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of VRA and the rest of the Retail-Wholesale group's stocks.

Sonoco (SON) Hits 52-Week High: What's Driving the Stock?

2018-09-13 zacks
Shares of Sonoco Products Company (SON - Free Report) crafted a 52-week high of $57.64 during intra-day trading, finally closing lower at $57.16 on Sep 12. The company has a market cap of $5.7 billion. Over the past three months, its average volume of shares traded has been approximately 422K. Also, Sonoco surpassed the Zacks Consensus Estimate in three of the trailing four quarters, the average positive earnings surprise being 3. (1-0)

Harsco (HSC) Soars to 52-Week High, Time to Cash Out?

2018-09-13 zacks
Have you been paying attention to shares of Harsco (HSC - Free Report) ? Shares have been on the move with the stock up 18.1% over the past month. The stock hit a new 52-week high of $29.15 in the previous session. Harsco has gained 53.6% since the start of the year compared to the -3.7% move for the Zacks Industrial Products sector and the 26.6% return for the Zacks Industrial Services industry.

CF (CF) Hits Fresh High: Is There Still Room to Run?

2018-09-12 zacks
Have you been paying attention to shares of CF Industries Holdings (CF - Free Report) ? Shares have been on the move with the stock up 9% over the past month. The stock hit a new 52-week high of $52.71 in the previous session. CF Industries Holdings has gained 23% since the start of the year compared to the -7.9% move for the Zacks Basic Materials sector and the 6.8% return for the Zacks Fertilizers industry.

Perficient (PRFT) Hits Fresh High: Is There Still Room to Run?

2018-09-11 zacks
Have you been paying attention to shares of Perficient (PRFT - Free Report) ? Shares have been on the move with the stock up 15.2% over the past month. The stock hit a new 52-week high of $31.09 in the previous session. Perficient has gained 61.3% since the start of the year compared to the 11.1% move for the Zacks Computer and Technology sector and the 9.2% return for the Zacks Computer - Services industry.

CUSIP: 92335C106